Featured Research

from universities, journals, and other organizations

New Drug Candidate Knocks Out Resistant Form Of Chronic Myeloid Leukemia

Date:
January 2, 2008
Source:
Oregon Health & Science University
Summary:
Researchers have found a new, experimental drug candidate it to be effective against a highly resistant mutation in chronic myeloid leukemia. Gleevec continues to be remarkably successful in the vast majority of patients. However, for those patients who develop resistance, incorporating a targeted T315I inhibitor such as SGX393 into the suite of available CML drugs in the clinic is urgently needed. This is not equivalent to cure, but it could potentially represent an important advance in disease management with CML inhibitor therapy.

Oregon Health & Science University Cancer Institute researchers have found a new, experimental drug candidate it to be effective against a highly resistant mutation in chronic myeloid leukemia (CML).

Related Articles


This drug candidate could build on the legacy of Gleevec, which has been the gold standard for treating this leukemia and was developed by Brian Druker, M.D., director of the OHSU Cancer Institute. Despite Gleevec's success, some CML patients develop resistance to Gleevec, often due to mutations that interfere with drug binding. The second-generation drugs Sprycel and Tasigna have been developed as largely successful treatments for Gleevec-resistant patients. However, one mutation, termed T315I, is completely resistant to all three clinical CML drugs and is a frequent cause of relapse.

Now, however, a new drug candidate, SGX393, has been found to inhibit most resistant mutations, including T315I, both in mouse models and in patient cells in laboratory studies. SGX393 was identified by SGX Pharmaceuticals Inc., a biotechnology company focusing on cancer therapeutics.

The OHSU Cancer Institute researchers took this a step further.

"Because none of the drugs controlled all of the known mutations, we extended our study to look at using combinations of the drugs," said Christopher Eide, research technician, hematology/medical oncology, OHSU School of Medicine.

"Remarkably, we found that the combination of SGX393 with either Sprycel or Tasigna completely suppressed resistant growth. Our findings raise the exciting possibility that inhibitor 'cocktails' may be sufficient to completely pre-empt drug resistance in CML," Eide said.

He is a co-author with OHSU Cancer Institute research scientist Thomas O'Hare, Ph.D., research specialist, hematology/medical oncology, OHSU School of Medicine.

The study was performed in the laboratory of Michael Deininger, M.D., Ph.D., associate professor of medicine, hematology/medical oncology, OHSU School of Medicine.

"What patients should know is that, with the addition of this drug candidate to the currently available set of clinical CML drugs, we may have the therapeutic tools to achieve and maintain even more effective and longer control of their disease," Bumm said.

Gleevec continues to be remarkably successful in the vast majority of patients. However, for those patients who develop resistance, incorporating a targeted T315I inhibitor such as SGX393 into the suite of available CML drugs in the clinic is urgently needed. This is not equivalent to cure, but it could potentially represent an important advance in disease management with CML inhibitor therapy.

SGX Pharmaceuticals, Inc. is targeting submitting an Investigational New Drug application for SGX393 in the first half of 2008.

OHSU has licensed some of the underlying technology used in this research to MolecularMD.


Story Source:

The above story is based on materials provided by Oregon Health & Science University. Note: Materials may be edited for content and length.


Cite This Page:

Oregon Health & Science University. "New Drug Candidate Knocks Out Resistant Form Of Chronic Myeloid Leukemia." ScienceDaily. ScienceDaily, 2 January 2008. <www.sciencedaily.com/releases/2007/12/071210163311.htm>.
Oregon Health & Science University. (2008, January 2). New Drug Candidate Knocks Out Resistant Form Of Chronic Myeloid Leukemia. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2007/12/071210163311.htm
Oregon Health & Science University. "New Drug Candidate Knocks Out Resistant Form Of Chronic Myeloid Leukemia." ScienceDaily. www.sciencedaily.com/releases/2007/12/071210163311.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Rural India's Low-Cost Sanitary Pad Revolution

Rural India's Low-Cost Sanitary Pad Revolution

AFP (Nov. 28, 2014) — One man hopes his invention -– a machine that produces cheap sanitary pads –- will help empower Indian women. Duration: 01:51 Video provided by AFP
Powered by NewsLook.com
Research on Bats Could Help Develop Drugs Against Ebola

Research on Bats Could Help Develop Drugs Against Ebola

AFP (Nov. 28, 2014) — In Africa's only biosafety level 4 laboratory, scientists have been carrying out experiments on bats to understand how virus like Ebola are being transmitted, and how some of them resist to it. Duration: 01:18 Video provided by AFP
Powered by NewsLook.com
WHO Says Male Ebola Survivors Should Abstain From Sex

WHO Says Male Ebola Survivors Should Abstain From Sex

Newsy (Nov. 28, 2014) — WHO cites four studies that say Ebola can still be detected in semen up to 82 days after the onset of symptoms. Video provided by Newsy
Powered by NewsLook.com
Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins